Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non Operating Income (2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Non Operating Income for 1 consecutive years, with -$128000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income changed N/A to -$128000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$421000.0, a N/A change, with the full-year FY2025 number at -$463000.0, changed N/A from a year prior.
  • Non Operating Income was -$128000.0 for Q4 2025 at Madrigal Pharmaceuticals, up from -$293000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of -$128000.0 in Q4 2025 to a low of -$293000.0 in Q3 2025.